High specific immune response to a bivalent anti-HPV vaccine in HIV-1-infected men in São Paulo, Brazil

Adriele Fontes a,b,1,*, Maria Antonieta Andreoli d,1, Luisa Lina Villa e,1, Tatiane Assone a,b,1, Karen Gaester a,b,1, Luiz A.M. Fonseca c,1, Alberto JS Duarte a,1, Jorge Casseb a,b,1,*

a Departamento de Radiologia e Oncologia, Faculdade de Medicina da Universidade de São Paulo, Brazil
b Instituto de Medicina Tropical de São Paulo, São Paulo, SP, Brazil
c HPV Institute, Santa Casa de São Paulo, Brazil
d Departamento de Medicina Preventiva, Faculdade de Medicina da Universidade de São Paulo, Brazil

* Corresponding authors at: Laboratory of Investigation in Dermatology and Immunodeficiencies – LIM56, Av. Dr. Eneas de Carvalho Aguiar 500, 3rd Floor, Building II, São Paulo, SP, Brazil. Tel.: +55 11 3061 7194; fax: +55 11 3081 7190. E-mail addresses: adrielefontes@gmail.com (A. Fontes), jcasseb10@gmail.com (J. Casseb).

1 Authors who contributed equally to this study.

Introduction

Human papillomavirus (HPV) infections rank among the most common virus sexually transmitted diseases worldwide [1]; it is an epitheliotropic virus, characterized by its icosahedral, non-encapsulated form, with a diameter of 50 nm, and includes as its genetic material a molecule of double-stranded circular DNA with approximately eight thousand base pairs [2]. To date, more than 200 types of human HPV have been described and classified into high and low risk subgroups; there are 45 potentially oncogenic types infecting the anogenital region [3].

HPV escapes recognition by the immune system by not causing cell lysis and not inducing a local inflammation [4]. In its infection cycle there is no viremia, and a very low amount of viral protein is expressed; also, the virus is not cytolytic. Thus, there is no signaling to the immune system to activate the innate response, as well as a delay in the adaptive response [1], leading to an immune dysfunction, with a decrease in the number of antigen-presenting cells (APCs) and T-cell lymphocytes. Immune surveillance is impaired, due both to a deficient presentation of antigens and to a reduced effector phase of T-lymphocyte activation and antibody production [5].

Anti-HPV vaccine was the result of the mastering of the key technologies that are capable of producing virus-like (VLP) particles. Recombinant DNA was used to generate VLPs able to mimic
the natural virus, causing high titers of neutralizing serum antibodies. Today there are two types of vaccines commercially available: Cervarix® (GlaxoSmithKline Biologicals website) containing VLPs (Virus Like Particle) types 16 and 18, Gardasil® (Merck Dohme Shape, Whitehouse Station, New Jersey) containing VLPs of types 6, 11, 16 and 18. Both vaccines contain an adjuvant aluminum salt that precipitates VLP allowing a more slowly release of the antigen [6,7]. More recently, a prophylactic nive-

VLPs of types 6, 11, 16 and 18. Both vaccines contain an adjuvant (Merck Dohme Shape, Whitehouse Station, New Jersey) containing available: Cervarix

bodies. Today there are two types of vaccines commercially

human papillomavirus vaccine (types 16 and 18), is a recombinant protein virus-like particle. It was administered by intramuscular injection 0.5 mL at 0, 4 and 24 weeks. The primary immunogenicity endpoint was determined three weeks after the third vaccination dose.

Design study

Twenty-five HIV-infected patients who met the inclusion criteria during data collection period were analyzed and classified as follows: All were vaccinated; however, six (24%) had anti-HPV antibodies at baseline, and were not considered further in the analysis. Therefore, 19 HIV-infected individuals were described in the study (nine patients with $T \text{CD}4 < 500 \text{ cells/mm}^3$ and 10 patients with $\text{CD}4 \geq 500 \text{ cells/mm}^3$). Control group was made up of five healthy adults who were negative for HIV and HCV infections.

Laboratory methods

Samples were collected by venipuncture from the peripheral blood of research subjects and processed in tubes containing 5 mL of gel; the tubes were centrifuged at 2000x$g$ at a room with a temperature of $15 \degree C$ for 15 min. Two aliquots of 500 $\mu l$ of serum were stored at $-80 \degree C$ in order to perform the analysis.

HPV serology

Presence of IgG antibodies to HPV 16 and 18 in the sera samples was detected using a type specific ELISA using L1VLPs from S. cerevisiae (kindly provided by Dr Ian Frazer, Univ of Queensland, Woolongaba, AU). Fifty microliters of 0.03 mg/ml of each VLP were used to coat the ELISA plates overnight at 4 $\degree C$. From every two wells coated with VLP, one was coated with PBS, pH 7.2. Plates were then washed once with PBST (0.02% Tween in PBS pH7.2) and blocked with 100 ml of BSA blocking solution (1.5% bovine serum Albumin in PBS) for 2 h. After the blocking step, plates were washed twice with PBST. Sera and control samples, diluted 1:50 with a solution of 5% fat free milk powder, 0.1% BSA in PBST, were tested in duplicate and incubated at 37 $\degree C$ for one hour. Plates were washed five times with PBST and tested with horseradish peroxidase conjugated with anti-human IgG (TagolImmunobiologials, USA) at appropriated dilutions. Following 45 min of incubation at 37 $\degree C$, the plates were washed 5 times with PBST and 50 microliters of ABTS solution (0.05% 2,2’-Azino Bis Ethylenebenzethiolazoline-6-sulfonic acid, Sigma, USA) were added to each well. The reaction was stopped after 4 min by adding 50 ml of 1% Sodium Dodecyl Sulfate. Optical Density (OD) was read at 415 nm in a microplate reader (Biorad, USA). The OD value for each serum was calculated by subtracting the mean OD of wells coated with VLP from the OD of wells coated with PBS. The cut points for seropositivity for HPV 16 and 18 were determined from the positive controls provided by WHO [15].

Results

Mean age of group A was 30.44 years, and most patients reported having a college degree (66.7%) and being single (77.8%). The average age of group B was 34, 50% reported having completed high school and 80% were single (these characteristics were not different).

Six patients had anti-HPV antibodies before baseline and therefore were excluded from further analysis. The remaining 19 HIV-infected patients and five controls had titers of anti-HPV antibodies below the cut-off of 0.216. Four weeks after the administration of the first dose of vaccine an increase in titers of

Material and methods

In total, 450 HIV-infected individuals have been in follow-up at our outpatient service for the last 25 years. Among them, 300 subjects are males; 56 of whom aged 18–45 years and were seen in the Clinic during the study. These patients underwent a screening to check for the presence of HPV in oral samples, previously published elsewhere [14]; eight tested positive for HPV and 23 had other exclusion criteria and were not vaccinated. Therefore, in this study, 25 patients satisfied the inclusion criteria, were invited and agreed to participate, all of them were men who make sex with men. Five HIV-negative control subjects were tested for HIV infection and submitted to an oral cleansing prior to vaccination. Patients and controls were recruited from October 2012 to February 2013. The Ethical Board of Hospital das Clínicas approved the clinical study; it is registered at the clinical trial identifier (NCT02236234).

Subject population

HIV-1-infected men aged 18–45 years old were invited to participate, regardless acquisition mode of transmission. We selected two groups according to the updated outpatient records: nine had T-CD4 cells counts above 500 cells/$\mu l$, whereas 16 had T-CD4 cells counts below 500. Exclusion criteria included other types of immunedeficiencies, such as renal failure or hepatic malignancies, autoimmune diseases, immunosuppressive medications, or other vaccination within the last 2–3 weeks. All patients gave informed consent, which contained information about the study. After agreeing to sign the term, they answered a questionnaire containing information on socio-behavioral, presence or history of sexually transmitted diseases, HIV viral load, CD4+$T$ cells count and time of the first HIV testing.

Vaccine

Cervarix® (GlaxoSmith-Kline, Brentford, England, a bivalent human papillomavirus vaccine (types 16 and 18), is a recombinant
circulating antibodies was detected. Three control subjects seroconverted (60%), as well as five patients in group A (55.6%) and three patients in group B (30%) as judged by increased antibody titers measured by ELISA using VLP 16 HPV ranked by standard titles (Fig. 1).

After the 2nd dose (at 30 days), four weeks after immunization, there was an increase in titers of circulating antibodies in the serum of patients. Four patients in the control group seroconverted (80%), eight patients in group A (88.8%) and eight patients in group B (80%) had increased titers of anti-HPV, ranked by titles’ standard. Finally, after the 3rd dose (at 180 days), four weeks after immunization, there was an increase in circulating antibodies in the serum of patients: five volunteers from the control group (100%), eight HIV-infected patients from group A (88.8%) and nine HIV-infected patients from group B (90%) seroconverted (Fig. 1) after vaccination.

Discussion

This study demonstrated that the bivalent HPV vaccine (Cervarix) was efficacious when administered to HIV-infected-oral-HPV- negative men, with more than 90 percent of patients producing antibodies to HPV in high titers, after a full vaccination scheme. It was also safe, with no major adverse effect reported. The satisfactory response of HIV patients to the vaccine was independent of their CD4 count, since both groups studied (CD4+ T-cells count < 500 and CD4+ T-cells count ≥ = 500 cells/mm³) responded similarly to the vaccine, with approximately 90% of seroconversion. Our results are in agreement with findings from other authors [9], who also worked with HIV-infected men, obtaining a 95% proportion of seroconversion with a tetravalent vaccine (2010) administered to seventy 12 years-old HIV-positive children [13]. Our data strongly suggest that HPV vaccination induces protective immunity against vaccine-specific HPV infection in persons with HIV [16]. Similarly, this efficacy was found in HIV-1-positive women from Africa [17].

The VLP-based bivalent vaccine administered to our patients did not change their CD4+ counts or HIV viral loads. These findings were also observed in two other studies involving immune depressed patients [13,18]. Several factors may contribute to the nearly absence of deleterious effects of the vaccine on the immune system, such as the intrinsic immunogenicity of the VLPs, keeping an orderly and repetitive arrangement of their epitopes, enabling a specific recognition by B cells. Another likely factor may be the characteristics of the epitopes of the L1 region, which induce a broad neutralizing antibody response, enabling the recognition of a certain type of HPV and its variants through its amino acids sequences.

The high titers of antibodies induced by VLP may inhibit the establishment of an infection through the occlusion of its binding sites on the cell. VLP may also avoid the immunologic escape of HPV, decreasing the expression of the capsid proteins, delaying the production of virions until the cell differentiation is complete [19]. Patients did not report any serious adverse effect that could be attributed to the vaccine, only minor complaints such as pain at the injection site and headaches, considered mild or moderate and similar to what has been observed for other vaccines when administered to HIV-infected patients [9,18,20].

The efficacy of the bivalent (16 and 18) HPV vaccine has been demonstrated in several other studies, with consistent, comparable results for the two currently used vaccines. The long term efficacy of the vaccine is unknown, and follow-up studies are currently been undertaken to examine whether a booster dose of the vaccine will be needed in the future [21]. On a previous study developed by our research team, Veiga et al. demonstrated that the viral load from HIV carriers was the determinant factor for the unsuccessful vaccination against hepatitis B [22]. Our results from the current study are in agreement with two other studies which found that the viral loads of HIV-1-infected patients, immunized with Merck’s tetravalent anti-HPV vaccine, were not associated with their response to the vaccine.

Our study has some limitations such as the small number of patients and controls, short follow-up time, precluding a better comparison with the HIV negative population. We also did not investigate the possibility of a cross-reaction of the vaccine with other HPV types not present on the vaccine; another aspect not contemplated on our study was the long term behavior of the antibodies’ titers in the patients sera. We hope that our results help stimulate the HPV immunization of the HIV-infected men, in order to decrease their risks of infection, morbidity and mortality from HPV diseases, as well as averting the risks of transmission.

Author contributions

A.S, M.A.A. and K.G collected the data and wrote the manuscript. L.A.M.F.; LLV and T.A.S. made the statistical analysis and revised the final version of the MS. A.J.S.D. and J.C. designed the study and read the final version of the MS.

Additional information

LLV was involved in clinical trials of the Quadrivalent HPV vaccine and is member of the board of Merck, Sharp and Dohme for HPV vaccines.
Competing financial interests

The authors declare no competing financial interests.

Acknowledgments

We thank the financial support from FAPESP, Grant 2010/07076-4, supported by grants to LLV from FAPESP 2008/05889-1 and CNPq 573799/2008-3. Our thanks to Dr. Roberto Carvalho from the Referral Center and Training in STD/AIDS – Sao Paulo for assistance in patient recruitment. Our thanks to all the patients who participated in this research.

References

[1] M. Stanley, HPV-immune response to infection and vaccination, Infect. Agents Cancer 5 (2010) 19.
[2] H. zur Hausen, E.M. de Villiers, L. Gissmann, Papillomavirus infections and human genital cancer, Gynecol. Oncol. 12 (1981) 5124–5128.
[3] B.E. Hoots, J.M. Palefsky, J.M. Pimenta, J.S. Smith, Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions, Int. J. Cancer J. Int. Du. Cancer 124 (2009) 2375–2383.
[4] J. Betiol, L.L. Villa, L. Sichero, Impact of HPV infection on the development of head and neck cancer, Braz. J. Med. Biol. Res. 46 (2013) 217–226.
[5] J.T. Schiller, D.R. Lowy, Understanding and learning from the success of prophylactic human papillomavirus vaccines, Nat. Rev. Microbiol. 10 (2012) 681–692.
[6] J.M. Palefsky, A.R. Giuliano, S. Goldstone, E.D. Moreira Jr., C. Aranda, H. Jessen, et al., HPV vaccine against anal HPV infection and anal intraepithelial neoplasia, New Engl. J. Med. 365 (2011) 1578–1585.
[7] N. Munoz, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler, et al., Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women, J. Natl. Cancer Inst. 102 (2010) 325–339.
[8] X. Castellsague, A.R. Giuliano, S. Goldstone, A. Guevara, O. Mogensen, J.M. Palefsky, et al., Immunogenicity and safety of the 9-valent HPV vaccine in men, Vaccine (2015).
[9] T. Wilkin, J.Y. Lee, S.Y. Lensing, E.A. Ster, S.E. Goldstone, J.M. Berry, et al., Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men, J. Infect. Dis. 202 (2010) 1246–1253.
[10] G. Ciavarra, A.T. Ho, D. Cobrinik, E. Zackenhaus, Critical role of the Rb family in myoblast survival and fusion, Plos One 6 (2011) e17682.
[11] G. Figliuolo, J. Maia, A.P. Jalck, A.E. Miranda, L.C. Ferreira, Clinical and laboratory study of HPV infection in men infected with HIV, Int. Braz. J. Urol.: Off. J. Braz. Soc. Urol. 38 (2012) 411–418.
[12] A. Kreuter, N.H. Brockmeyer, S.J. Weissenhorn, T. Gambichler, M. Stucker, P. Allmeyer, et al., Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia, J. Investig. Dermatol. 128 (2008) 2316–2324.
[13] M.J. Levin, A.B. Moscicki, L.Y. Song, T. Fenton, W.A. Meyer 3rd, J.S. Read, et al., Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HPV-infected children 7 to 12 years old, J. Acquir. Immune Defic. Syndr. 55 (2010) 197–204.
[14] X. Gaaster, L.A. Fonseca, O. Luzi, T. Assone, A.S. Fontes, F. Costa, et al., Human papillomavirus infection in oral fluids of HIV-1-positive men: prevalence and risk factors, Sci. Rep. 4 (2014) 6592.
[15] M. Ferguson, A. Heath, S. Johnes, S. Pagliusi, J. Dillner, Collaborative Study P. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses, Int. J. Cancer J. Int. Du. Cancer 118 (2006) 1508–1514.
[16] L. Toft, M. Tolstrup, M. Storgaard, L. Ostergaard, O.S. Sogaard, Vaccination and its relationship with T CD45RA+(naive) and CD45RO+(memory) sub-sets in HIV-1-infected subjects, Vaccine 24 (2006) 7124–7128.